Entering text into the input field will update the search result below

Vaxxinity IPO: Pioneering Vaccines For Chronic Diseases

Nov. 01, 2021 1:14 PM ETVaxxinity, Inc. (VAXX)4 Comments


  • Vaxxinity is pioneering the development of vaccines for chronic diseases.
  • The Company uses a proprietary synthetic peptide based technology in-licensed from a related party and significant investor.
  • The Company has filed a registration statement for an IPO of $100 million worth of Class A Common Stock.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »



Vaxxinity, Inc. (NASDAQ:VAXX) is a clinical stage biotechnology company advancing its synthetic peptide vaccine platform (‘Vaxxine platform) that has the potential to enable a new class of therapeutics harnessing the human body’s innate immune system, to provide improved quality and convenience

A Healthcare Worker Prepares a Dose of COVID-19 Vaccine.

Morsa Images/DigitalVision via Getty Images

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-

Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 

This article was written by

Avisol Capital Partners profile picture

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

They lead the investing group Total Pharma Tracker where they offer a monthly updated catalyst database, an investability scoring system for quick reference ideas, and direct access in chat for dialogue and questions. Learn more.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (4)

Arbrapatat profile picture
@Avisol Capital Partners thank you for the informative article. Would you have any insight / views regarding competition and Vaxxinity's unique advantages? In doing a surface search, Axon Neuroscience for instance claims to have the largest dedicated Alzheimer peptide vaccine research team (see article here: www.biospace.com/... )

Vaxxinity CEO was on the 7investing podcast this week, interesting discussion.
cdgingrich profile picture
I will pass on a biotech whose mission sounds like it came from an sjw.
joezapp profile picture
"As I have said before, it is nearly impossible to do a valuation of an emerging biopharma..."

I commented on another biopharma article earlier that you put out, before seeing this lengthy explanation. Thanks for the explanation. "Like" works for me. So would "dislike", "doesn't thrill us", "neutral", "somewhat interesting", and "intrigued".
Avisol Capital Partners profile picture
@joezapp Thanks, and I kind of said the same thing in response to your other comment - tough to put a number, don't want to commit, but necessary to cover these early stage cos factually.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.